Tarsus Pharmaceuticals (TARS) Change in Receivables (2019 - 2026)

Tarsus Pharmaceuticals' Change in Receivables history runs 8 years deep, the most recent figure standing at -$189000.0 for Q1 2026.

• In Q1 2026, Change in Receivables fell 144.06% year-over-year to -$189000.0; the TTM figure through Mar 2026 stood at $37.7 million (up 24.83% YoY), while the FY2025 annual figure was $38.3 million, up 27.07% from the prior year.
• Change in Receivables was -$189000.0 for Q1 2026 at Tarsus Pharmaceuticals, down from $37.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $37.9 million in Q4 2025 to a low of -$12.9 million in Q3 2024.
• Historically, Change in Receivables has averaged $3.9 million across 5 years, with a median of $179000.0 in 2025.
• Biggest YoY gain for Change in Receivables was 14605.88% in 2023; the steepest drop was 46088.24% in 2023.
• A 5-year view of Change in Receivables shows it stood at -$17000.0 in 2022, then plunged by 46088.24% to -$7.9 million in 2023, then surged by 483.18% to $30.1 million in 2024, then grew by 25.9% to $37.9 million in 2025, then tumbled by 100.5% to -$189000.0 in 2026.
• The last three Change in Receivables figures came in at -$189000.0 (Q1 2026), $37.9 million (Q4 2025), and -$190000.0 (Q3 2025), per Business Quant data.